First to clinics support for biologics in
- Innovative and biosimilar biologics molecules (mammalian and microbial origin)
- USP/DSP process development speed up
- CDMO selection and evaluation
- Technological fit evaluation
- Comparability and biosimilarity strategy
- Regulatory CMC pathway and support
- Facility readiness support for regulatory inspections
- Mock inspections for EMA and FDA submissions